

## ASX ANNOUNCEMENT

### Appendix 4C – Quarterly Cash Flow Report

#### Highlights for the quarter ended 30<sup>th</sup> September 2017

- **Cash balance as of 30<sup>th</sup> September, \$444k**
- **Completion of entitlement offer in October raise \$1,334K**
- **Sufficient capital with options to fund into 2019**
- **Company on track with commercialisation plan**
- **Commenced data collection from PeriCoach version 3 (V3) device (released in May)**
- **Commenced data collection from 8-week challenge (released in May)**
- **Development of analysis software in final stage**

**31<sup>st</sup> October 2017:** Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System and AutoStart® infusion system, has today released its Appendix 4C - Quarterly Cashflow report for period ending 30 September 2017.

The total cash outflow was \$790k, approximately 16% less than projected. Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$20k, with extremely limited commercial activity occurring. Analytica is a research and development company, and doesn't have the resources to market our products. The sales provide independent users feedback for refining the PeriCoach.

In October the company received \$1,334k from share entitlement offer with the issue of 318.6 Million shares. On the basis of continued support by shareholders in this entitlement issue for the exercise of options in January 2018 and May 2018, Analytica will have adequate capital to carry through well into calendar 2019.

The Board and management appreciate the confidence of our shareholders for supporting the entitlement offer. These funds are being deployed to continue the development of the PeriCoach system with the rollout of V3 and advance negotiations with a potential partner.

An application for research and development tax incentive is being finalised to entitle the company to claim an estimate of \$850k tax refund as a result of research and development expenditure this last 12 months. The company also has a \$400k loan facility. Directors are monitoring capital requirements to ensure the company has adequate cash to continue development of and undertake partnering negotiations for the PeriCoach and AutoStart products.

PeriCoach is a regulated medical device built with a powerful data collection system. The system is providing new insights into management and motivation of the conservative treatment pathway for female pelvic floor disorders. This core capability is the driver for the pursuit of clinical evidence in the forms of studies and surveys as well as development of enhanced functionality of the PeriCoach system. Analytica have enrolled participants in a study to evidence the superior capability of the PeriCoach V3. This study includes the effectiveness of the 8-week program. Continued investment in real world data-gathering tools to increase the sophistication of analysis of user behaviour and pelvic health information is the cornerstone of company strategy.

The enhanced functionality in V3 for users simplifies progress improvement reporting, incorporates symptom trackers, provides intuitive training guidance, and elevates the "in-app" experience. The release of the structured



exercise program additionally addresses motivation and success factors to drive consistency and correct technique, which data demonstrates as key factors to conservative treatment success. The capabilities of the V3 expands the market opportunity for PeriCoach and adds to the appeal for a potential licensing partner.

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

Follow us on:



#### About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from [pericoach.com](http://pericoach.com) in Australia and New Zealand, UK and Ireland, and in the USA.



## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Analytica Ltd

**ABN**

12 006 464 866

**Quarter ended ("current quarter")**

September 2017

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	20	20
1.2 Payments for		
(a) research and development	(337)	(337)
(b) product manufacturing and operating costs	2	2
(c) advertising and marketing	(52)	(52)
(d) leased assets		
(e) staff costs	(276)	(276)
(f) administration and corporate costs	(119)	(119)
1.3 Dividends received (see note 3)		
1.4 Interest received	2	2
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(760)</b>	<b>(760)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	(3)	(3)
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(d) intellectual property		
	(e) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	<b>Net cash from / (used in) investing activities</b>	<b>(3)</b>	<b>(3)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of shares		
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options	(5)	(5)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	<b>Net cash from / (used in) financing activities</b>	<b>(5)</b>	<b>(5)</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	1,212	1,212
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(760)	(760)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3)	(3)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(5)	(5)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	<b>Cash and cash equivalents at end of quarter</b>	<b>444</b>	<b>444</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	444	444
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>444</b>	<b>444</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
123
0

--

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000

--

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	400	0
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		
Capital raising received \$1,334k in October.		

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	350
9.2 Product manufacturing and operating costs	45
9.3 Advertising and marketing	50
9.4 Leased assets	
9.5 Staff costs	270
9.6 Administration and corporate costs	130
9.7 Other (provide details if material)	
<b>9.8 Total estimated cash outflows</b>	<b>845</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

### **Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: ..... Date: .....  
(Director)

Print name: R. Mangelsdorf 31 Oct 2017

### **Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.